US Stock MarketDetailed Quotes

G Genpact

Watchlist

37.500
+5.100+15.74%

Close Aug 9 16:00 ET

37.500
0.0000.00%

Post 20:02 ET

6.68BMarket Cap10.59P/E (TTM)

Genpact Stock Forum

NSIKAN DICKSON

May 15 12:28

$Genpact (G.US)$

Decoding liquidity ratios

Moomoo AI

Feb 8 07:20

Genpact's strategy to strengthen its leadership team with digital leaders to drive growth, leveraging data, technology, and AI-first principles is emphasized in new appointments. CEO BK Kalra is excited about the potential for these appointments to drive Genpact into its next chapter of growth.

Press Release: Genpact Propels AI-First Strategy With New Executive Leadership Appointments

Moomoo AI

Feb 3 08:52

Genpact's increasing ROCE and its ability to consistently reinvest in itself is a highly sought after trait. The company's promising trends may not be fully recognized by investors yet, suggesting a potential opportunity if other metrics and valuation align.

Genpact (NYSE:G) Is Doing The Right Things To Multiply Its Share Price

Moomoo AI

Jan 4 05:12

Extensive share selling by Genpact insiders hints at their belief that the stock isn't cheap. Despite company's growing earnings and some shares owned by insiders, purchasing should be carefully considered due to larger selling than buying.

Genpact Insiders Sell US$5.2m Of Stock, Possibly Signalling Caution

Anonymous122170

Dec 30, 2023 09:03

$Genpact (G.US)$

Genpact(G) Post-Mkt Price 34.710 0.00%

Moomoo AI

Dec 17, 2023 08:00

Given Genpact's cheaper price compared to its peers and the predicted profit growth, this could be a good investment opportunity. Its potential growth may not be fully priced in yet. But, assess its strong balance sheet and financial health for a smart decision.

Is Now The Time To Look At Buying Genpact Limited (NYSE:G)?

Moomoo AI

Nov 6, 2023 13:31

Genpact's performance, noted for substantial business reinvestment and high returns, has led to remarkable earnings growth. Yet, its growth rate trails the industry average, suggesting areas for enhancement. The company's future payout ratio is projected to decrease to 17% in the coming three years, with no major changes expected in its ROE.